Should I Buy IMUX? IMUX 2026 Analysis

Should You Buy Immunic Inc (IMUX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.620

1 Day change

5.26%

52 Week Range

1.390

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: trend is still bearish (SMA_200 > SMA_20 > SMA_5) with weakening momentum (MACD histogram negative and expanding).
Price (pre-market ~0.621) is below the pivot (0.649), implying overhead resistance and a less favorable immediate entry.
Options positioning looks aggressively call-skewed (put/call OI ratio 0.03), but volume is tiny today; sentiment signal is noisy rather than confirmatory.
No fresh news catalysts in the last week to force an upside re-rate near-term.
Analysts are bullish with very high upside vs the current price, but fundamentals remain pre-revenue with continuing losses—this is more “optionality on trials” than an immediate technical buy setup.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend: Bearish structure (SMA_200 > SMA_20 > SMA_5) signals the broader downtrend remains intact.
Momentum: MACD histogram -0.00173 (below 0) and negatively expanding → downside momentum is strengthening.
RSI: RSI_6 ~40.46 (neutral-to-weak) → not oversold enough to suggest a high-confidence snapback entry.
Key levels: Support S1 ~0.596 then S2 ~0.563; Resistance/pivot ~0.649 then R1 ~0.702 (and R2 ~0.735).
Near-term pattern odds (from similar candlesticks): modest 1-day/1-week upside bias but negative 1-month expectation (-1.18%), consistent with a weak intermediate trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Call open interest 15,089 vs put open interest 425 → extremely call-heavy (bullish skew / speculative upside betting).
Liquidity/flow today: Total volume 35 calls and 0 puts; despite high “today vs avg” ratios, the absolute tape is small → sentiment read is fragile.
Volatility: 30D IV ~559.67% with IV percentile ~94% (very elevated) → market is pricing extreme event risk; common in micro-cap biotech but increases the chance of sharp moves both ways.
Takeaway: Options skew is bullish, but it does not outweigh the bearish chart trend without a catalyst or a technical reversal signal.

Technical Summary

Sell

Buy

Positive Catalysts

- Bullish Street view remains: recent initiations/coverage maintain Buy ratings with multi-dollar price targets, implying strong upside optionality if clinical progress validates the thesis.
- Options open interest heavily favors calls (put/call OI 0.03), indicating traders are positioned for upside scenarios.
- No significant hedge fund or insider selling trends flagged recently (neutral read).

Neutral/Negative Catalysts

- No news in the last week: lack of a near-term catalyst reduces the probability of an immediate breakout.
- Bearish technical setup (downtrend MAs + deteriorating MACD) suggests rallies may get sold into resistance (pivot ~0.649 / R1 ~0.702).
- Elevated IV signals the market expects big moves; without directionally supportive catalysts, this can translate into sharp downside spikes.
- Congress/politician activity: no recent data available (no supportive “influential buyer” signal).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: 0 (no operating revenue base yet).
Net income: -$25.579M (loss), ~4.97% YoY improvement, but still meaningfully negative.
EPS: -0.13, down ~45.83% YoY (worsened per-share loss), indicating dilution and/or higher per-share loss dynamics.
Overall: financial profile remains development-stage/pre-revenue; price action will likely be driven more by trial/catalyst timing than quarter-to-quarter fundamentals.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst activity is net bullish but mixed on targets:
- 2025-11-07: Roth Capital initiated with Buy, PT $3.
- 2025-11-14: H.C. Wainwright reiterated Buy, cut PT $10 → $8 (share count adjustment post-Q3).
Pros (Wall St view): belief in vidofludimus calcium’s potential advantages in MS indications; Phase 2 data cited for anti-inflammatory + neuroprotection narrative.
Cons: price target cut reflects dilution/share count realities; execution and clinical/regulatory timeline risk remains the core debate.
Net: analysts lean positive, but this is a thesis-driven biotech call rather than confirmation from current trend/earnings strength.

5 Analyst Rating

Wall Street analysts forecast IMUX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMUX is 4.25 USD with a low forecast of 3 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.589

Low

Averages

4.25

High

Current: 0.589

Low

Averages

4.25

High

H.C. Wainwright

Buy

downgrade

$10 -> $8

AI Analysis

2025-11-14

Reason

H.C. Wainwright

Price Target

$10 -> $8

AI Analysis

2025-11-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Immunic to $8 from $10 and keeps a Buy rating on the shares. The firm adjusted the company's share count post the Q3 report.

Roth Capital

Boobalan Pachaiyappan

Buy

initiated

2025-11-07

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

2025-11-07

initiated

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Immunic with a Buy rating and $3 price target. The firm says the company has "potential best-in-indication advantages" of vidofludimus calcium in relapsing-remitting multiple sclerosis and progressive multiple sclerosis. This is validated by Immunic's Phase 2 data that demonstrated simultaneous anti-inflammation and neuroprotection, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMUX

Unlock Now

IMUX Should I Buy

IMUX Should I Buy

Should You Buy Immunic Inc (IMUX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch